pISSN 1976-2283
eISSN 2005-1212

Download original image
Fig. 4. Mean symptom intensity score per week for sequence A (venlafaxine first and placebo second) (A) and sequence B (placebo first and venlafaxine second) groups (B), respectively. The linear mixed model with a random subject effect is performed to determine the carryover effect, the period effect, and the treatment effect of the drug for the ranks of the symptom intensity score in the repeated measure cross-over design. Venlafaxine treatment resulted in a significantly lower symptom intensity score when compared with the placebo treatment (p<0.001).
Gut Liver 2012;6:1~9 https://doi.org/10.5009/gnl.2012.6.1.1
© Gut and Liver